These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35256538)

  • 1. Polo-like kinases as potential targets and PLK2 as a novel biomarker for the prognosis of human glioblastoma.
    Ding Y; Liu H; Zhang C; Bao Z; Yu S
    Aging (Albany NY); 2022 Mar; 14(5):2320-2334. PubMed ID: 35256538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer.
    Zeng Y; Li N; Liu W; Zeng M; Cheng J; Huang J
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2447-2460. PubMed ID: 32627077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DYRK1A-mediated PLK2 phosphorylation regulates the proliferation and invasion of glioblastoma cells.
    Tan S; Zhao J; Wang P
    Int J Oncol; 2023 Aug; 63(2):. PubMed ID: 37387444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low expression or hypermethylation of PLK2 might predict favorable prognosis for patients with glioblastoma multiforme.
    Xia X; Cao F; Yuan X; Zhang Q; Chen W; Yu Y; Xiao H; Han C; Yao S
    PeerJ; 2019; 7():e7974. PubMed ID: 31763067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer.
    Kressin M; Fietz D; Becker S; Strebhardt K
    Cells; 2021 May; 10(5):. PubMed ID: 34065956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-mitotic functions of polo-like kinases in cancer cells.
    Raab CA; Raab M; Becker S; Strebhardt K
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma.
    Pezuk JA; Brassesco MS; Morales AG; de Oliveira JC; de Paula Queiroz RG; Machado HR; Carlotti CG; Neder L; Scrideli CA; Tone LG
    Cancer Gene Ther; 2013 Sep; 20(9):499-506. PubMed ID: 23887645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.
    Tandle AT; Kramp T; Kil WJ; Halthore A; Gehlhaus K; Shankavaram U; Tofilon PJ; Caplen NJ; Camphausen K
    Eur J Cancer; 2013 Sep; 49(14):3020-8. PubMed ID: 23790466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of PLKs expression and prognosis in breast cancer.
    Jiawei W; Xiajun B; Tian S; Xuzheng G; Zhenwang Z
    Cancer Genet; 2022 Nov; 268-269():83-92. PubMed ID: 36206661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Putative link between Polo-like kinases (PLKs) and Toll-like receptor (TLR) signaling in transformed and primary human immune cells.
    El Maadidi S; Weber ANR; Motshwene P; Schüssler JM; Backes D; Dickhöfer S; Wang H; Liu X; Garcia MD; Taumer C; Soufi B; Wolz OO; Klimosch SN; Franz-Wachtel M; Macek B; Gay NJ
    Sci Rep; 2019 Sep; 9(1):13168. PubMed ID: 31511529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling.
    Alafate W; Xu D; Wu W; Xiang J; Ma X; Xie W; Bai X; Wang M; Wang J
    J Exp Clin Cancer Res; 2020 Nov; 39(1):239. PubMed ID: 33176854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.
    Syed N; Smith P; Sullivan A; Spender LC; Dyer M; Karran L; O'Nions J; Allday M; Hoffmann I; Crawford D; Griffin B; Farrell PJ; Crook T
    Blood; 2006 Jan; 107(1):250-6. PubMed ID: 16160013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal induction of polo-like kinases (Plks) and impact of Plk2 on cell cycle progression in the rat ovary.
    Li F; Jo M; Curry TE; Liu J
    PLoS One; 2012; 7(8):e41844. PubMed ID: 22870256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
    Strebhardt K; Becker S; Matthess Y
    Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis.
    Pezuk JA; Brassesco MS; de Oliveira RS; Machado HR; Neder L; Scrideli CA; Tone LG
    Childs Nerv Syst; 2017 Apr; 33(4):609-615. PubMed ID: 28283778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polo-like kinases and oncogenesis.
    Eckerdt F; Yuan J; Strebhardt K
    Oncogene; 2005 Jan; 24(2):267-76. PubMed ID: 15640842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
    Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
    Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of potential crucial genes and molecular mechanisms in glioblastoma multiforme by bioinformatics analysis.
    Chen X; Pan Y; Yan M; Bao G; Sun X
    Mol Med Rep; 2020 Aug; 22(2):859-869. PubMed ID: 32467990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current assessment of polo-like kinases as anti-tumor drug targets.
    Craig SN; Wyatt MD; McInnes C
    Expert Opin Drug Discov; 2014 Jul; 9(7):773-89. PubMed ID: 24819909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polo-like kinases in AML.
    Berg T; Bug G; Ottmann OG; Strebhardt K
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1069-74. PubMed ID: 22667760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.